Use of FGF-2 and FGF-18 to direct bone marrow stromal stem cells to chondrogenic and osteogenic lineages

References

• Caplan AI. Why are MSCs therapeutic? New data: new insight. J. Pathol. 217(2), 318–324 (2009).
   PubMed Web of Science ®Google Scholar
• Caplan AI. New era of cell-based orthopedic therapies. Tissue Eng. B Rev. 15(2), 195–200 (2009).
   PubMed Web of Science ®Google Scholar
• Trounson A, Mcdonald C. Stem cell therapies in clinical trials: progress and challenges. Cell Stem Cell 17(1), 11–22 (2015).
   PubMed Web of Science ®Google Scholar
• Murphy M, Barry F. Cellular chondroplasty: a new technology for joint regeneration. J. Knee Surg. 28(1), 45–50 (2015).
   PubMed Web of Science ®Google Scholar
• Barry F, Murphy M. Mesenchymal stem cells in joint disease and repair. Nat. Rev. Rheumatol. 9(10), 584–594 (2013).
   PubMed Web of Science ®Google Scholar
• Acosta FL Jr, Lotz J, Ames CP. The potential role of mesenchymal stem cell therapy for intervertebral disc degeneration: a critical overview. Neurosurg. Focus 19(3), E4 (2005).
   PubMedGoogle Scholar
• Hiyama A, Mochida J, Sakai D. Stem cell applications in intervertebral disc repair. Cell. Mol. Biol. (Noisy-le-grand) 54(1), 24–32 (2008).
   PubMed Web of Science ®Google Scholar
• Leung VY, Chan D, Cheung KM. Regeneration of intervertebral disc by mesenchymal stem cells: potentials, limitations, and future direction. Eur. Spine J. 15(Suppl. 3), S406–S413 (2006).
   PubMedGoogle Scholar
• Ghosh P, Moore RD, Vernon-Roberts B et al. Immunoselected STRO-3+mesenchymal precursor cells and restoration of the extracellular matrix of degenerate intervertebral discs. J Neurosurgery 16(5), 479–488 (2012).
   Web of Science ®Google Scholar
• Wei A, Chung SA, Tao H et al. Differentiation of rodent bone marrow mesenchymal stem cells into intervertebral disc-like cells following coculture with rat disc tissue. Tissue Eng. A 15(9), 2581–2595 (2009).
   PubMed Web of Science ®Google Scholar
• Gaetani P, Torre ML, Klinger M et al. Adipose-derived stem cell therapy for intervertebral disc regeneration: an in vitro reconstructed tissue in alginate capsules. Tissue Eng. A 14(8), 1415–1423 (2008).
   PubMed Web of Science ®Google Scholar
• Chen S, Emery SE, Pei M. Coculture of synovium-derived stem cells and nucleus pulposus cells in serum-free defined medium with supplementation of transforming growth factor-beta1: a potential application of tissue-specific stem cells in disc regeneration. Spine (Phila Pa 1976) 34(12), 1272–1280 (2009).
   PubMed Web of Science ®Google Scholar
• Murrell W, Sanford E, Anderberg L, Cavanagh B, Mackay-Sim A. Olfactory stem cells can be induced to express chondrogenic phenotype in a rat intervertebral disc injury model. Spine J. 9(7), 585–594 (2009).
   PubMed Web of Science ®Google Scholar
• Quintin A, Schizas C, Scaletta C et al. Isolation and in vitro chondrogenic potential of human foetal spine cells. J. Cell. Mol. Med. 13(8B), 2559–2569 (2009).
   PubMed Web of Science ®Google Scholar
• Correa D, Somoza RA, Lin P et al. Sequential exposure to fibroblast growth factors (FGF) 2, 9 and 18 enhances hMSC chondrogenic differentiation. Osteoarthritis Cartilage 23(3), 443–453 (2015).
   PubMed Web of Science ®Google Scholar
• Ellman MB, Yan D, Ahmadinia K, Chen D, An HS, Im HJ. Fibroblast growth factor control of cartilage homeostasis. J. Cell. Biochem. 114(4), 735–742 (2013).
   PubMed Web of Science ®Google Scholar
• Shimoaka T, Ogasawara T, Yonamine A et al. Regulation of osteoblast, chondrocyte, and osteoclast functions by fibroblast growth factor (FGF)-18 in comparison with FGF-2 and FGF-10. J. Biol. Chem. 277(9), 7493–7500 (2002).
   PubMed Web of Science ®Google Scholar
• Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol. 2(3), REVIEWS3005 (2001).
   PubMed Web of Science ®Google Scholar
• Ornitz DM, Marie PJ. FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev. 16(12), 1446–1465 (2002).
   PubMed Web of Science ®Google Scholar
• Chuang CY, Lord MS, Melrose J et al. Heparan sulfate-dependent signaling of fibroblast growth factor 18 by chondrocyte-derived perlecan. Biochemistry 49(26), 5524–5532 (2010).
   PubMed Web of Science ®Google Scholar
• Knox S, Merry C, Stringer S, Melrose J, Whitelock J. Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors. J. Biol. Chem. 277(17), 14657–14665 (2002).
   PubMed Web of Science ®Google Scholar
• Handorf AM, Li WJ. Fibroblast growth factor-2 primes human mesenchymal stem cells for enhanced chondrogenesis. PLoS ONE 6(7), e22887 (2011).
   PubMed Web of Science ®Google Scholar
• Shu C, Smith SS, Little CB, Melrose J. Comparative immunolocalisation of perlecan, heparan sulphate, fibroblast growth factor-18, and fibroblast growth factor receptor-3 and their prospective roles in chondrogenic and osteogenic development of the human foetal spine. Eur. Spine J. 22(8), 1774–1784 (2013).
   PubMed Web of Science ®Google Scholar
• Smith SM, Shu C, Melrose J. Comparative immunolocalisation of perlecan with collagen II and aggrecan in human foetal, newborn and adult ovine joint tissues demonstrates perlecan as an early developmental chondrogenic marker. Histochem. Cell Biol. 134(3), 251–263 (2010).
   PubMed Web of Science ®Google Scholar
• Verma RP, Hansch C. Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs. Bioorg. Med. Chem. 15(6), 2223–2268 (2007).
   PubMed Web of Science ®Google Scholar
• Smith SM, Whitelock JM, Iozzo RV, Little CB, Melrose J. Topographical variation in the distributions of versican, aggrecan and perlecan in the foetal human spine reflects their diverse functional roles in spinal development. Histochem. Cell Biol. 132(5), 491–503 (2009).
   PubMed Web of Science ®Google Scholar
• Chuang CY, Shahin K, Lord MS, Melrose J, Doran PM, Whitelock JM. The cartilage matrix molecule components produced by human foetal cartilage rudiment cells within scaffolds and the role of exogenous growth factors. Biomaterials 33(16), 4078–4088 (2012).
   PubMed Web of Science ®Google Scholar
• Melrose J, Hayes AJ, Whitelock JM, Little CB. Perlecan, the “Jack of all trades” proteoglycan of cartilaginous weight-bearing connective tissues. Bioessays 30(5), 457–469 (2008).
   PubMed Web of Science ®Google Scholar
• Ehrlich G, Khaltaev Ng. Low Back Pain Initiative WHO/NCD/NCM/CRA/99.1 152 (1999). http://apps.who.int/iris/bitstream/10665/66296/1/WHO_NCD_NCM_CRA_99.1.pdf.
   Google Scholar
• Weir C, Morel-Kopp MC, Gill A et al. Mesenchymal stem cells: isolation, characterisation and in vivo fluorescent dye tracking. Heart Lung Circ. 17(5), 395–403 (2008).
   PubMed Web of Science ®Google Scholar
• Dominici M, Le Blanc K, Mueller I et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8(4), 315–317 (2006).
   PubMed Web of Science ®Google Scholar
• Cheung WM, Ng WW, Kung AW. Dimethyl sulfoxide as an inducer of differentiation in preosteoblast MC3T3-E1 cells. FEBS Lett. 580(1), 121–126 (2006).
   PubMed Web of Science ®Google Scholar
• Melrose J, Smith SM, Smith MM, Little CB. The use of Histochoice for histological examination of articular and growth plate cartilages, intervertebral disc and meniscus. Biotech. Histochem. 83(1), 47–53 (2008).
   PubMed Web of Science ®Google Scholar
• Melrose J, Shu C, Young C et al. Mechanical destabilization induced by controlled annular incision of the IVD dysregulates MMP expression and induces disc degeneration. Spine (Phila Pa 1976) 37(1), 18–25 (2012).
   PubMed Web of Science ®Google Scholar
• Melrose J, Smith S, Ghosh P. Histological and immunohistological studies on cartilage. Methods Mol. Med. 101, 39–63 (2004).
   PubMedGoogle Scholar
• Caplan AI. MSCs: the sentinel and safe-guards of injury. J. Cell. Physiol. 231(7), 1413–1416 (2016).
   PubMed Web of Science ®Google Scholar
• Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J. Cell. Biochem. 98(5), 1076–1084 (2006).
   PubMed Web of Science ®Google Scholar
• Lai WT, Krishnappa V, Phinney DG. Fibroblast growth factor 2 (Fgf2) inhibits differentiation of mesenchymal stem cells by inducing Twist2 and Spry4, blocking extracellular regulated kinase activation, and altering Fgf receptor expression levels. Stem Cells 29(7), 1102–1111 (2011).
   PubMed Web of Science ®Google Scholar
• Spector JA, Mathy JA, Warren SM et al. FGF-2 acts through an ERK1/2 intracellular pathway to affect osteoblast differentiation. Plast. Reconstr. Surg. 115(3), 838–852 (2005).
   PubMed Web of Science ®Google Scholar
• Johnstone B, Hering TM, Caplan AI, Goldberg VM, Yoo JU. In vitro chondrogenesis of bone marrow-derived mesenchymal progenitor cells. Exp. Cell Res. 238(1), 265–272 (1998).
   PubMed Web of Science ®Google Scholar
• Barry F, Boynton RE, Liu B, Murphy JM. Chondrogenic differentiation of mesenchymal stem cells from bone marrow: differentiation-dependent gene expression of matrix components. Exp. Cell Res. 268(2), 189–200 (2001).
   PubMed Web of Science ®Google Scholar
• Chen WH, Lai MT, Wu AT et al. In vitro stage-specific chondrogenesis of mesenchymal stem cells committed to chondrocytes. Arthritis Rheum. 60(2), 450–459 (2009).
   PubMedGoogle Scholar
• Chen G, Deng C, Li YP. TGF-beta and BMP signaling in osteoblast differentiation and bone formation. Int. J. Biol. Sci. 8(2), 272–288 (2012).
   PubMed Web of Science ®Google Scholar
• Munger JS, Sheppard D. Cross talk among TGF-beta signaling pathways, integrins, and the extracellular matrix. Cold Spring Harb. Perspect. Biol. 3(11), a005017 (2011).
   PubMed Web of Science ®Google Scholar
• Fischer J, Dickhut A, Rickert M, Richter W. Human articular chondrocytes secrete parathyroid hormone-related protein and inhibit hypertrophy of mesenchymal stem cells in coculture during chondrogenesis. Arthritis Rheum. 62(9), 2696–2706 (2010).
   PubMedGoogle Scholar
• Guo J, Chung UI, Yang D, Karsenty G, Bringhurst FR, Kronenberg HM. PTH/PTHrP receptor delays chondrocyte hypertrophy via both Runx2-dependent and -independent pathways. Dev. Biol. 292(1), 116–128 (2006).
   PubMed Web of Science ®Google Scholar
• Stheneur C, Dumontier MF, Guedes C et al. Basic fibroblast growth factor as a selective inducer of matrix Gla protein gene expression in proliferative chondrocytes. Biochem. J. 369(Pt 1), 63–70 (2003).
   PubMedGoogle Scholar
• Chen S, Young MF, Chakravarti S, Birk DE. Interclass small leucine-rich repeat proteoglycan interactions regulate collagen fibrillogenesis and corneal stromal assembly. Matrix Biol. 35, 103–111 (2014).
   PubMed Web of Science ®Google Scholar
• Douglas T, Heinemann S, Bierbaum S, Scharnweber D, Worch H. Fibrillogenesis of collagen types I, II, and III with small leucine-rich proteoglycans decorin and biglycan. Biomacromolecules 7(8), 2388–2393 (2006).
   PubMed Web of Science ®Google Scholar
• Reese SP, Underwood CJ, Weiss JA. Effects of decorin proteoglycan on fibrillogenesis, ultrastructure, and mechanics of type I collagen gels. Matrix Biol. 32(7–8), 414–423 (2013).
   PubMed Web of Science ®Google Scholar
• Ferdous Z, Wei VM, Iozzo R, Hook M, Grande-Allen KJ. Decorin-transforming growth factor-interaction regulates matrix organization and mechanical characteristics of three-dimensional collagen matrices. J. Biol. Chem. 282(49), 35887–35898 (2007).
   PubMed Web of Science ®Google Scholar
• Roughley PJ. The structure and function of cartilage proteoglycans. Eur. Cells Mater. 12, 92–101 (2006).
   PubMed Web of Science ®Google Scholar
• Schaefer L, Iozzo RV. Biological functions of the small leucine-rich proteoglycans: from genetics to signal transduction. J. Biol. Chem. 283(31), 21305–21309 (2008).
   PubMed Web of Science ®Google Scholar
• Iozzo RV, Schaefer L. Proteoglycans in health and disease: novel regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans. FEBS J. 277(19), 3864–3875 (2010).
   PubMed Web of Science ®Google Scholar
• Iozzo R, Goldoni S, Berendson Ad, Young Mf. Small leucine rich proteoglycans. In: The Extracellular Matrix: an Overview. Mecham R ( Ed.). Springer Berlin, Heidelberg 197–231 (2011).
   Google Scholar
• Border WA, Noble NA, Yamamoto T et al. Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature 360(6402), 361–364 (1992).
   PubMed Web of Science ®Google Scholar
• Yamaguchi Y, Mann DM, Ruoslahti E. Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature 346(6281), 281–284 (1990).
   PubMed Web of Science ®Google Scholar
• Waddington RJ, Roberts HC, Sugars RV, Schonherr E. Differential roles for small leucine-rich proteoglycans in bone formation. Eur. Cells Mater. 6, 12–21; discussion 12 (2003).
   PubMedGoogle Scholar
• Mochida Y, Duarte WR, Tanzawa H, Paschalis EP, Yamauchi M. Decorin modulates matrix mineralization in vitro. Biochem. Biophys. Res. Commun. 305(1), 6–9 (2003).
   PubMed Web of Science ®Google Scholar
• Takagi M, Yamada T, Kamiya N, Kumagai T, Yamaguchi A. Effects of bone morphogenetic protein-2 and transforming growth factor-beta1 on gene expression of decorin and biglycan by cultured osteoblastic cells. Histochem. J. 31(6), 403–409 (1999).
   PubMedGoogle Scholar
• Melrose J, Isaacs MD, Smith SM et al. Chondroitin sulphate and heparan sulphate sulphation motifs and their proteoglycans are involved in articular cartilage formation during human foetal knee joint development. Histochem. Cell Biol. 138(3), 461–475 (2012).
   PubMed Web of Science ®Google Scholar
• Melrose J, Roughley P, Knox S, Smith S, Lord M, Whitelock J. The structure, location, and function of perlecan, a prominent pericellular proteoglycan of fetal, postnatal, and mature hyaline cartilages. J. Biol. Chem. 281(48), 36905–36914 (2006).
   PubMed Web of Science ®Google Scholar
• Melrose J, Smith S, Cake M, Read R, Whitelock J. Perlecan displays variable spatial and temporal immunolocalisation patterns in the articular and growth plate cartilages of the ovine stifle joint. Histochem. Cell Biol. 123(6), 561–571 (2005).
   PubMed Web of Science ®Google Scholar
• Whitelock JM, Melrose J, Iozzo RV. Diverse cell signaling events modulated by perlecan. Biochemistry 47(43), 11174–11183 (2008).
   PubMed Web of Science ®Google Scholar
• Inkinen RI, Lammi MJ, Lehmonen S, Puustjarvi K, Kaapa E, Tammi MI. Relative increase of biglycan and decorin and altered chondroitin sulfate epitopes in the degenerating human intervertebral disc. J. Rheumatol. 25(3), 506–514 (1998).
   PubMed Web of Science ®Google Scholar
• Caterson B. Fell-Muir Lecture: chondroitin sulphate glycosaminoglycans: fun for some and confusion for others. Int. J. Exp. Pathol. 93(1), 1–10 (2012).
   PubMed Web of Science ®Google Scholar
• Solchaga LA, Penick K, Goldberg VM, Caplan AI, Welter JF. Fibroblast growth factor-2 enhances proliferation and delays loss of chondrogenic potential in human adult bone-marrow-derived mesenchymal stem cells. Tissue Eng. A 16(3), 1009–1019 (2010).
   PubMed Web of Science ®Google Scholar
• Solchaga LA, Penick K, Porter JD, Goldberg VM, Caplan AI, Welter JF. FGF-2 enhances the mitotic and chondrogenic potentials of human adult bone marrow-derived mesenchymal stem cells. J. Cell. Physiol. 203(2), 398–409 (2005).
   PubMed Web of Science ®Google Scholar
• Shu C, Smith SS, Little CB, Melrose J. Comparative immunolocalisation of perlecan, heparan sulphate, fibroblast growth factor-18, and fibroblast growth factor receptor-3 and their prospective roles in chondrogenic and osteogenic development of the human foetal spine. Eur. Spine J. 22(8), 1774–1841 (2013).
   PubMed Web of Science ®Google Scholar